ArticleJournal of thoracic disease2019
Hyperprogressive disease: a distinct effect of immunotherapy?
Article in Journal of thoracic disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Hyperprogression of brain metastases following initiation of immune checkpoint inhibitors.Journal of neuro-oncology · 2025Article
- Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer.The oncologist · 2024Article
- Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report.Journal of medical case reports · 2022Article
- The dark side of immunotherapy.Annals of translational medicine · 2021Review
- The Potential of T Cell Factor 1 in Sustaining CD8Cancers · 2021Review
- TGF-β inhibition can overcome cancer primary resistance to PD-1 blockade: A mathematical model.PloS one · 2021Article
- Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report.Frontiers in oncology · 2021Article
- Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy.Cancers · 2020Review
- Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature.Journal of cancer research and clinical oncology · 2020Review
- PD-1 Blockade Aggravates Epstein-Barr VirusFrontiers in oncology · 2020Article
- The dark side of immunotherapy: challenges facing the new hope in cancer treatment.Annals of translational medicine · 2019Article
- Immunotherapy Use in Patients With Lung Cancer and Comorbidities.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.